Related Experiment Video
Updated: May 20, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors
Frank Bennett1, Hollis S Kezar, Vinay Girijavallabhan
1Merck Research Laboratories, Kenilworth, NJ 07033, USA. frank.bennett@merck.com
Abstract:
Introduction of nitrogen atom into the benzene ring of a previously identified HCV replication (replicase) benzofuran inhibitor 2, resulted in the discovery of the more potent pyridofuran analogue 5. Subsequent introduction of small alkyl and alkoxy ligands into the pyridine ring resulted in further improvements in replicon potency. Replacement of the 4-chloro moiety on the pyrimidine core with a methyl group, and concomitant monoalkylation of the C-2 amino moiety resulted in the identification of several inhibitors with desirable characteristics. Inhibitor 41, from the monosubstituted pyridofuran and inhibitor 50 from the disubstituted series displayed excellent potency, selectivity (GAPDH/MTS CC(50)) and PK parameters in all species studied, while the selectivity in the thymidine incorporation assay (DNA·CC(50)) was low.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes
Inhibitors of Bacterial DNA Synthesis
Subviral Agents
Retrovirus Life Cycles
Hepatitis

